Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes

Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes

Myelodysplastic syndromes and chronic myelomonocytic leukemia are blood disorders characterized by ineffective hematopoiesis and progressive marrow failure that can transform into acute leukemia. The DNA methyltransferase inhibitor 5-azacytidine (AZA) is the most effective pharmacological option, bu...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Unnikrishnan, A, Deshpande, NP, Verma, A, Kumari, A, Richards, LA, Knezevic, K, Chandrakanthan, V, Thoms, JAI, Tursky, ML, Huang, Y, Ali, Z, Olivier, J, Galbraith, S, Kulasekararaj, AG, Tobiasson, M, Karimi, M, Pellagatti, A, Wilson, SR, Lindeman, R, Young, B, Ramakrishna, R, Arthur, C, Stark, R, Crispin, P, Curnow, J, Warburton, P, Roncolato, F, Boultwood, J, Lynch, K, Jacobsen, SEW, Mufti, GJ, Hellstrom-Lindberg, E, Wilkins, MR, MacKenzie, KL, Wong, JWH, Campbell, PJ, Pimanda, JE
التنسيق:	Journal article
اللغة:	English
منشور في:	Cell Press 2017

مواد مشابهة

Myelodysplastic syndromes: moving towards personalized management
حسب: Eva Hellström-Lindberg, وآخرون
منشور في: (2020-07-01)

Spliceosome mutations: 1 plus 1 does not always equal 2
حسب: Pellagatti, A, وآخرون
منشور في: (2020)

Reduced translation of GATA1 in Diamond-Blackfan anemia.
حسب: Boultwood, J, وآخرون
منشور في: (2014)

SF3B1 mutant myelodysplastic syndrome: Recent advances
حسب: Pellagatti, A, وآخرون
منشور في: (2020)

Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
حسب: Pellagatti, A, وآخرون
منشور في: (2016)

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
حسب: Jädersten, M, وآخرون
منشور في: (2009)

Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes
حسب: Follo, M, وآخرون
منشور في: (2019)

P557: HEMATOLOGIC IMPROVEMENTS WITH IVOSIDENIB + AZACITIDINE COMPARED WITH PLACEBO + AZACITIDINE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA
حسب: H. Dohner, وآخرون
منشور في: (2022-06-01)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk myelodysplastic syndrome: the Phase 3, randomized, ENHANCE Study
حسب: Garcia-Manero, G, وآخرون
منشور في: (2021)

Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q- syndrome.
حسب: Boultwood, J, وآخرون
منشور في: (2012)

5q- syndrome.
حسب: Boultwood, J, وآخرون
منشور في: (2012)

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
حسب: Svensson, T, وآخرون
منشور في: (2014)

P556: CHANGES IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA RECEIVING IVOSIDENIB + AZACITIDINE OR PLACEBO + AZACITIDINE
حسب: A. Schuh, وآخرون
منشور في: (2022-06-01)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): the phase 3, randomized, ENHANCE study
حسب: Garcia-Manero, G, وآخرون
منشور في: (2021)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndromes (MDS): the Phase 3, randomized, ENHANCE Study
حسب: Garcia-Manero, G, وآخرون
منشور في: (2021)

PHASE 2 STUDY OF PEVONEDISTAT + AZACITIDINE VERSUS AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES/CHRONIC MYELOMONOCYTIC LEUKEMIA OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA (NCT02610777)
حسب: L. Adès, وآخرون
منشور في: (2020-11-01)

P430: MOLECULAR CHARACTERIZATION OF CLINICAL RESPONSE IN NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE
حسب: S. de Botton, وآخرون
منشور في: (2022-06-01)

Gene expression profiling of day 7 erythroblasts from RARS before and after treatment with G-CSF
حسب: Nikpour, M, وآخرون
منشور في: (2007)

Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells
حسب: Pellagatti, A, وآخرون
منشور في: (2009)

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
حسب: R Edlin, وآخرون
منشور في: (2010-05-01)

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
حسب: R Edlin, وآخرون
منشور في: (2010-05-01)

P748: SINGLE CELL GENOTYPING OF MATCHED BONE MARROW AND PERIPHERAL BLOOD CELLS IN TREATMENT NAIVE AND AZA-TREATED MDS AND CMML
حسب: A. Schnegg-Kaufmann, وآخرون
منشور في: (2022-06-01)

MDS-197: Magrolimab + azacitidine versus azacitidine + placebo in untreated higher-risk (HR) myelodysplastic syndromes (MDS): the phase 3, randomized, ENHANCE study
حسب: Garcia-Manero, G, وآخرون
منشور في: (2021)

Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes (British Journal of Haematology (2008) 142, (57-64))
حسب: Pellagatti, A, وآخرون
منشور في: (2009)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome.
حسب: Pellagatti, A, وآخرون
منشور في: (2011)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
حسب: Pellagatti, A, وآخرون
منشور في: (2010)

Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes.
حسب: Pellagatti, A, وآخرون
منشور في: (2008)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome
حسب: Pellagatti, A, وآخرون
منشور في: (2011)

Del(5q) Myelodysplastic Stem Cells Exhibit Their Clonal Advantage Via Increased Adhesion to the Microenvironment
حسب: Scharenberg, C, وآخرون
منشور في: (2011)

Gene expression profiling in the myelodysplastic syndromes.
حسب: Pellagatti, A, وآخرون
منشور في: (2005)

A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes
حسب: Sara Mongiorgi, وآخرون
منشور في: (2023-02-01)

Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches
حسب: Armstrong, R, وآخرون
منشور في: (2017)

Advances in the 5q- syndrome.
حسب: Boultwood, J, وآخرون
منشور في: (2010)

Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.
حسب: Pellagatti, A, وآخرون
منشور في: (2010)

The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many?
حسب: Anjali Bhatt, وآخرون
منشور في: (2022-11-01)

A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine
حسب: Chiara R. Dart, وآخرون
منشور في: (2021-07-01)

NEW INSIGHTS INTO THE BIOLOGY OF REFRACTORY ANEMIA WITH RING SIDEROBLASTS (RARS) AND IDENTIFICATION OF ERYTHROID G-CSF TARGETS BY GENE EXPRESSION PROFILING
حسب: Nikpour, M, وآخرون
منشور في: (2009)

YI1 Gene expression profiling of day 7 erythroblasts from refractory anemia with ringed sideroblasts (RARS) and microarray-based identification of erythroid granulocyte-CSF (G-CSF) targets
حسب: Nikpour, M, وآخرون
منشور في: (2009)

Gene expression profiling of day 7 erythroblasts from refractory anemia with ringed sideroblasts (RARS) and microarray-based identification of erythroid granulocyte-CSF (G-CSF) targets
حسب: Nikpour, M, وآخرون
منشور في: (2009)

Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of G-CSF.
حسب: Nikpour, M, وآخرون
منشور في: (2010)